Amarantus Subsidiary Elto Pharma Receives
Notice of Allowance for European Patent Application Covering Method
of Treating Cognitive Impairment Associated with Alzheimer's
Disease and Parkinson's disease with
Eltoprazine
- Once Issued, patent extends coverage for Eltoprazine in Europe
into 2029
CEO to present at RedChip's Global Online Growth Conference on
December 7, 2017
San Francisco, CA -- December 5, 2017 -- InvestorsHub
NewsWire -- Amarantus Bioscience Holdings, Inc.
(OTCPK:
AMBS), a US-based biotechnology holding company with
wholly-owned subsidiaries developing first-in-class orphan
neurologic, regenerative medicine and ophthalmic therapies, today
announced that its wholly-owned subsidiary Elto Pharma, Inc. has
received an Intent to Grant a Patent notice from the European
Patent Office (EPO) for Eltoprazine. The notice refers to the
patent application "Treatment for Neurological and Mental
Disorders," and covers the method of treating cognitive impairment
or dysfunction associated with Parkinson's disease, Alzheimer's
disease, Mild Cognitive Impairment, dementia, or certain other
neurological disorders with Eltoprazine. Once issued, the patent
will extend Elto Pharma's intellectual property exclusivity for
Eltoprazine in Europe into 2029. Elto Pharma is currently
redesigning its Phase 2b clinical study for Eltoprazine in the
treatment of Levodopa-induced dyskinesia (PD-LID), targeted to
begin enrollment in 2018. Eltoprazine has received Orphan Drug
Designation from the US FDA for Eltoprazine in the treatment of
PD-LID.
Redchip Global Online Growth Conference
Amarantus President & CEO Gerald Commissiong is scheduled to
present at RedChip's Global Online Growth Conference on December
7th, 2017, at 2:30p.m. Eastern time. The presentation can be viewed
at www.RedChip.com. A live Q&A session will follow
the investor presentation.
RedChip's Global Online Growth Conference brings together
investors and executives of leading microcap companies,
representing a broad spectrum of industries and sectors, including
oil & gas, technology, mining, healthcare, consumer goods,
energy, and more. More than 10,000 investors attend RedChip's
microcap conference series each year. No registration is required
to participate in the conference. Start times are subject to
change.
Contact Redchip for further Information:
Bruce Haase
RedChip Companies
Phone: 407-644-4256
Email bruce@redchip.com
About Amarantus Bioscience Holdings, Inc.
Amarantus Bioscience Holdings (AMBS)
is a biotechnology company developing treatments and diagnostics
for diseases in the areas of neurology, regenerative medicine and
orphan diseases through its subsidiaries. AMBS' wholly-owned
subsidiary Elto Pharma, Inc. has development rights to eltoprazine,
a Phase 2b-ready small molecule indicated for Parkinson's disease
levodopa-induced dyskinesia, Alzheimer's aggression and adult ADHD.
AMBS acquired the rights to the Engineered Skin Substitute program
(ESS), a regenerative medicine-based approach for treating severe
burns with full-thickness autologous skin grown in tissue culture
that is being pursued by AMBS' wholly-owned subsidiary Cutanogen
Corporation. AMBS' wholly-owned subsidiary MANF Therapeutics, Inc.
owns key intellectual property rights and licenses from a number of
prominent universities related to the development of the
therapeutic protein known as mesencephalic astrocyte-derived
neurotrophic factor (MANF). MANF Therapeutics, Inc. is developing
MANF-based products as treatments for brain and ophthalmic
disorders. MANF was discovered by the Company's Chief Scientific
Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from
AMBS' proprietary discovery engine PhenoGuard. AMBS also owns
approximately 80 million shares of Avant Diagnostics, Inc. via the
sale of its wholly-owned subsidiary Amarantus Diagnostics, Inc.
that occurred in May 2016.
For further information please visit www.Amarantus.com, or connect with the Amarantus on
Facebook, LinkedIn, Twitter and Google+.
About Elto Pharma, Inc.
Eltoprazine is a small molecule 5HT1A/1B partial agonist in
clinical development for the treatment of Parkinson's disease
levodopa-induced dyskinesia (PD-LID), Alzheimer's aggression and
adult attention deficit hyperactivity disorder (adult ADHD).
Eltoprazine has been evaluated in over 680 human subjects to date,
and has a well-established safety profile, with statistically
significant efficacy results across multiple central nervous system
indications.
Eltoprazine was originally developed by Abbott Pharmaceuticals
in aggression-related indications. The eltoprazine program was
out-licensed to PsychoGenics, Inc. (PGI). PGI licensed eltoprazine
to Amarantus in 2014 after a successful proof-of-concept trial in
PD-LID.
In April 2017, Amarantus incorporated the wholly-owned
subsidiary Elto Pharma, Inc. to focus
Forward-Looking Statements
Certain statements, other than purely historical information,
including estimates, projections, statements relating to our
business plans, objectives, and expected operating results, and the
assumptions upon which those statements are based, are
forward-looking statements. These forward-looking statements
generally are identified by the words "believes," "project,"
"expects," "anticipates," "estimates," "intends," "strategy,"
"plan," "may," "will," "would," "will be," "will continue," "will
likely result," and similar expressions. Forward-looking statements
are based on current expectations and assumptions that are subject
to risks and uncertainties which may cause actual results to differ
materially from the forward-looking statements. Our ability to
predict results or the actual effect of future plans or strategies
is inherently uncertain. Factors which could have a material
adverse effect on our operations and future prospects on a
consolidated basis include, but are not limited to: changes in
economic conditions, legislative/regulatory changes, availability
of capital, interest rates, competition, and generally accepted
accounting principles. These risks and uncertainties should also be
considered in evaluating forward-looking statements and undue
reliance should not be placed on such statements.
Amarantus Investor and Media Contact:
Ascendant Partners, LLC
Richard Galterio
+1-732-410-9810
rich@ascendantpartnersllc.com
Source: Amarantus Bioscience Holdings, Inc.